Hashemi Mohammad, Rezaei Maryam, Narouie Behzad, Simforoosh Nasser, Basiri Abbas, Ziaee Sayed Amir Mohsen, Bahari Gholamreza, Taheri Mohsen
Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran; Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences , Zahedan, Iran.
Mol Cell Oncol. 2016 Apr 15;3(6):e1169342. doi: 10.1080/23723556.2016.1169342. eCollection 2016.
Lysosome associated protein transmembrane 4 β (LAPTM4B) is an oncogene associated with many human cancers. In the present study we aimed to examine the possible association between polymorphism and risk of prostate cancer (PCa) in an Iranian population. This case control study was performed on 168 patients with PCa and 176 controls with benign prostatic hyperplasia (BPH). Genomic DNA was extracted from whole blood and genotypes were identified by polymerase chain reaction. The distributions of genotypes were significantly different between PCa patients (60.7% for *1/1, 32.8% for *1/2, and 6.5% for *2/2) and controls (44.9% for *1/1, 49.4% for *1/2, and 5.7% for *2/2). Both the *1/2 and *1/2+*2/2 genotypes significantly decreased the risk of PCa compared with the 1/1 genotype (OR = 49, 95% CI = 0.31-0.77, p = 0.002 and OR = 0.53, 95% CI = 0.34-0.81, p = 0.004, respectively). The minor allele (LAPTM4B2) was associated with a decreased risk of PCa compared with the *1 allele (OR = 0.68, 95% CI = 0.48-0.96, p = 0.031). Moreover, polymorphism was not associated with clinicopathological characteristics of PCa patients. The results of this study showed that *2 was associated with a decreased risk of PCa but the clinicopathological characteristics of PCa were not linked to polymorphism. Further studies with larger sample sizes and different ethnicities are needed to confirm our findings.
溶酶体相关蛋白跨膜4β（LAPTM4B）是一种与多种人类癌症相关的癌基因。在本研究中，我们旨在探讨伊朗人群中该基因多态性与前列腺癌（PCa）风险之间的可能关联。这项病例对照研究对168例PCa患者和176例良性前列腺增生（BPH）对照进行。从全血中提取基因组DNA，并通过聚合酶链反应鉴定基因型。PCa患者（*1/1为60.7%，*1/2为32.8%，*2/2为6.5%）和对照（*1/1为44.9%，1/2为49.4%，2/2为5.7%）之间基因型分布存在显著差异。与1/1基因型相比，1/2和1/2+2/2基因型均显著降低了PCa风险（OR分别为0.49，95%CI = 0.31 - 0.77，p = 0.002；OR = 0.53，95%CI = 0.34 - 0.81，p = 0.004）。与1等位基因相比，次要等位基因（LAPTM4B2）与PCa风险降低相关（OR = 0.68，95%CI = 0.48 - 0.96，p = 0.031）。此外，该基因多态性与PCa患者的临床病理特征无关。本研究结果表明，*2与PCa风险降低相关，但PCa的临床病理特征与该基因多态性无关。需要更大样本量和不同种族的进一步研究来证实我们的发现。
